Key Insights

Highlights

Success Rate

91% trial completion (above average)

Published Results

258 trials with published results (26%)

Research Maturity

708 completed trials (71% of total)

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 40/100

Termination Rate

7.3%

73 terminated out of 1001 trials

Success Rate

90.7%

+4.2% vs benchmark

Late-Stage Pipeline

23%

227 trials in Phase 3/4

Results Transparency

36%

258 of 708 completed with results

Key Signals

258 with results91% success73 terminated

Data Visualizations

Phase Distribution

719Total
Not Applicable (191)
Early P 1 (5)
P 1 (147)
P 2 (149)
P 3 (106)
P 4 (121)

Trial Status

Completed708
Unknown124
Terminated73
Withdrawn47
Recruiting27
Not Yet Recruiting9

Trial Success Rate

90.7%

Benchmark: 86.5%

Based on 708 completed trials

Clinical Trials (1001)

Showing 20 of 20 trials
NCT04701437Not ApplicableActive Not RecruitingPrimary

Advanced Care Coordination and Enhanced Linkage and Retention Among Transitional Re-Entrants

NCT07037277Phase 3Recruiting

C-Forward: Efficacy and Safety of BEM/RZR vs SOF/VEL in Subjects With Chronic HCV

NCT00001971Recruiting

Evaluation of Patients With Liver Disease

NCT05042544RecruitingPrimary

The Australian HCV Point-of-Care Testing Program

NCT00004850CompletedPrimary

Epidemiology, Infectivity and Natural History of Hepatitis C Virus Infection

NCT01280825Recruiting

The 1200 Patients Project: Studying the Implementation of Clinical Pharmacogenomic Testing

NCT05390424Not ApplicableRecruiting

Screening for Hepatitis B, Hepatitis C and AIDS Viruses Using Dried Blood Spot

NCT07237282Phase 1Not Yet RecruitingPrimary

A Phase 1 Clinical Trial of Adjuvanted Protein-based HCV Vaccine Candidates (HCV Vaccine Trial)

NCT05208697Not ApplicableActive Not Recruiting

Tele-Harm Reduction

NCT04036396Not ApplicableCompleted

Mobile Enhanced Prevention Support for People Leaving Jail

NCT07040319Phase 1Not Yet RecruitingPrimary

Study of the Pharmacokinetics and Safety of Glecaprevir/Pibrentasvir Initiated in Pregnancy in Women With Hepatitis C With and Without HIV

NCT04493385Recruiting

The Hepatitis C Transplant Collaborative

NCT00630058Phase 1CompletedPrimary

A Phase 1 Study of MP-424, Peginterferon Alfa 2b, and Ribavirin in Hepatitis C

NCT00780416Phase 3CompletedPrimary

Efficacy and Safety of MP-424/Peginterferon Alfa-2b/Ribavirin Combination in Treatment-Naïve Patients With Chronic Hepatitis C

NCT00781274Phase 3CompletedPrimary

Efficacy and Safety of MP-424, Peginterferon Alfa-2b and Ribavirin in Chronic Hepatitis C Who Have Not Achieved an Undetectable HCV RNA Level With Previous Interferon Based Therapy

NCT00621296Phase 2CompletedPrimary

Safety and Efficacy of MP-424 to Treat Chronic Hepatitis C

NCT06367465RecruitingPrimary

Feasibility and Acceptability of HCV Treatment in Pregnancy

NCT04162938Not ApplicableRecruitingPrimary

Use of a Patient-Centered Electronic App to Increase ED Patient's Knowledge on HCV to Improve the HCV Care Continuum

NCT05127187Not ApplicableCompleted

Estimation of the Prevalence of HIV, Hepatitis C and Hepatitis B Infection Among Detainees in the Nîmes Administrative Detention Center

NCT04508907Phase 4Active Not RecruitingPrimary

A Study to Evaluate Preemptive Therapy in Hepatitis C (HCV) Organ Transplant Recipients

Scroll to load more

Research Network

Activity Timeline